Patents by Inventor Tibor Schomber

Tibor Schomber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210230300
    Abstract: The present invention is related to an inhibitor or antagonist of SHP2 for the treatment and/or prevention of a neoplastic disease.
    Type: Application
    Filed: May 28, 2019
    Publication date: July 29, 2021
    Applicant: Bayer Aktiengesellschaft
    Inventors: Ulf BRÜGGEMEIER, Tibor SCHOMBER, Karoline DRÖBNER, David ENGEL, Michael BECKER
  • Publication number: 20160009776
    Abstract: The present disclosure provides PDGFRbeta-Fc fusion proteins, or biologically active fragments thereof, comprising an extracellular domain of PDGFRbeta, or a biologically active fragment thereof, a linker and a Fc domain, wherein said fusion protein binds one or more of platelet-derived growth factor ligands with high affinity. The PDGFRbeta-Fc fusion proteins, or biologically active fragments thereof, accordingly, can be used to treat pathological neovascularization and fibrosis, e.g. cancer, ocular neovascular disorders or nephropathies. The disclosure also provides methods for treating ocular neovascular disorders with these fusion proteins without increasing vascular leakage. Such PDGFRbeta-Fc fusion proteins, or biologically active fragments thereof, exhibit increased terminal half time in the eye.
    Type: Application
    Filed: July 10, 2014
    Publication date: January 14, 2016
    Inventors: Lars Linden, Thomas Schlange, Andreas Wilmen, Mark Trautwein, Tibor Schomber, Michael Bottger, Jürgen Klar, Simone Greven